These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 37037319)
1. Impact of a real-time diagnostic and antimicrobial stewardship workflow on time to appropriate therapy for infections caused by multidrug-resistant Gram-negative organisms. McCrink KA; DeRonde KJ; Jimenez A; Rosello G; Natori Y; Claeys KC; Martinez OV; De Pascale B; Perez-Cardona A; Abbo LM; Vega AD Int J Antimicrob Agents; 2023 Jun; 61(6):106811. PubMed ID: 37037319 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276 [TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923 [TBL] [Abstract][Full Text] [Related]
5. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764 [No Abstract] [Full Text] [Related]
7. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
8. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
9. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199 [TBL] [Abstract][Full Text] [Related]
10. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Jean SS; Gould IM; Lee WS; Hsueh PR; Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206 [TBL] [Abstract][Full Text] [Related]
13. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524 [TBL] [Abstract][Full Text] [Related]
14. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam. Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465 [TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
16. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms. Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044 [TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019. Jean SS; Lee YL; Hsu CW; Hsueh PR Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
20. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]